Industry & Policy News

[Ivy Brain Tumor Center] In an effort to discover new treatments for brain tumors, such as glioblastoma, the Ivy Brain Tumor Center at Barrow Neurological Institute, announced the initiation of a ground-breaking Phase 0 clinical trial that tests a new experimental drug delivery method called superselective intra-arterial infusion, or SSIAI.

[ImPact Biotech (GlobalNewswire)] ImPact Biotech announced the FDA granted Orphan Drug Designation to Padeliporfin Vascular Targeted Photodynamic therapy (VTP) for the treatment of patients with locally advanced pancreatic cancer.

[Allen Institute] The Allen Institute for Immunology has announced that researchers and staff will collaborate with private industry researchers to aid in the detailed, molecular understanding of disease, in service of developing new treatments and therapies to improve human health.

[Nature] In October 2020, John Carlisle reported a startling estimate of the number of clinical-trial studies in medical journals that are fake or fatally flawed. For more than 150 trials, Carlisle got access to anonymized individual participant data and judged that 44% of the trials contained at least some flawed data.

[Tenpoint Therapeutics] Tenpoint Therapeutics announced its launch with a $70 million Series A financing to develop its regenerative medicine platform to replace multiple cell types lost to inherited and age-related conditions.

[University at Buffalo] The National Cancer Institute awarded Dr. Ruogang Zhao, professor of biomedical engineering at the University at Buffalo (UB), and a colleague a five-year, $3 million R01 research grant to study immune cell therapy for solid tumors.